S. Malamud

722 total citations
40 papers, 539 citations indexed

About

S. Malamud is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, S. Malamud has authored 40 papers receiving a total of 539 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in S. Malamud's work include Metabolism and Genetic Disorders (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Breast Cancer Treatment Studies (5 papers). S. Malamud is often cited by papers focused on Metabolism and Genetic Disorders (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Breast Cancer Treatment Studies (5 papers). S. Malamud collaborates with scholars based in United States, Japan and Guatemala. S. Malamud's co-authors include B. Culliney, Peter Homel, Ricardo A. Cruciani, Jeanne Lapin, Russell K. Portenoy, Nora Esteban-Cruciani, Manjeet Chadha, Anthony M. Berson, Edward Rosenblatt and Jay E. Gold and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of the New York Academy of Sciences.

In The Last Decade

S. Malamud

40 papers receiving 521 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Malamud United States 12 242 177 128 90 81 40 539
Winston Ueno United States 8 265 1.1× 197 1.1× 113 0.9× 18 0.2× 19 0.2× 13 531
J. Hartlapp Germany 13 150 0.6× 187 1.1× 117 0.9× 24 0.3× 20 0.2× 48 483
Pamela Bacon United Kingdom 8 229 0.9× 34 0.2× 150 1.2× 9 0.1× 59 0.7× 22 490
Marcio M. Gomes Canada 17 126 0.5× 88 0.5× 404 3.2× 13 0.1× 19 0.2× 55 757
Yutaro Kato Japan 14 214 0.9× 449 2.5× 211 1.6× 51 0.6× 5 0.1× 76 752
Frederick M. Schnell United States 8 199 0.8× 192 1.1× 136 1.1× 38 0.4× 60 0.7× 17 481
Ángel Segura Spain 15 462 1.9× 143 0.8× 125 1.0× 43 0.5× 11 0.1× 45 881
Yıldız Okuturlar Türkiye 13 149 0.6× 94 0.5× 70 0.5× 12 0.1× 7 0.1× 55 475
Elif Erkan United States 16 20 0.1× 106 0.6× 105 0.8× 63 0.7× 88 1.1× 24 687
Yukiko Takahashi Japan 12 71 0.3× 116 0.7× 77 0.6× 29 0.3× 42 0.5× 34 362

Countries citing papers authored by S. Malamud

Since Specialization
Citations

This map shows the geographic impact of S. Malamud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Malamud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Malamud more than expected).

Fields of papers citing papers by S. Malamud

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Malamud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Malamud. The network helps show where S. Malamud may publish in the future.

Co-authorship network of co-authors of S. Malamud

This figure shows the co-authorship network connecting the top 25 collaborators of S. Malamud. A scholar is included among the top collaborators of S. Malamud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Malamud. S. Malamud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Miyashita, Hirotaka, Christina M. Cruz, & S. Malamud. (2020). Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate. Breast Cancer Research and Treatment. 182(2). 381–388. 12 indexed citations
2.
Miyashita, Hirotaka, et al.. (2020). Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis. Breast Cancer Research and Treatment. 181(2). 279–289. 11 indexed citations
3.
Miyashita, Hirotaka, et al.. (2020). Neo‐adjuvant therapy for triple‐negative breast cancer: Insights from a network meta‐analysis. The Breast Journal. 26(9). 1717–1728. 2 indexed citations
4.
Boolbol, Susan K., Manjeet Chadha, Laurie Kirstein, et al.. (2019). Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score® test. Breast Cancer Research and Treatment. 177(3). 611–618. 3 indexed citations
5.
Borson, R., Graydon Harker, James A. Reeves, et al.. (2012). Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer. Clinical Breast Cancer. 12(5). 322–330. 7 indexed citations
6.
7.
Cruciani, Ricardo A., Peter Homel, S. Malamud, et al.. (2006). Safety, Tolerability and Symptom Outcomes Associated with l-Carnitine Supplementation in Patients with Cancer, Fatigue, and Carnitine Deficiency: A Phase I/II Study. Journal of Pain and Symptom Management. 32(6). 551–559. 69 indexed citations
8.
Frank, Douglas K., Kenneth S. Hu, B. Culliney, et al.. (2005). Planned Neck Dissection after Concomitant Radiochemotherapy for Advanced Head and Neck Cancer. The Laryngoscope. 115(6). 1015–1020. 68 indexed citations
9.
Cruciani, Ricardo A., Peter Homel, B. Culliney, et al.. (2004). l‐Carnitine Supplementation for the Treatment of Fatigue and Depressed Mood in Cancer Patients with Carnitine Deficiency: A Preliminary Analysis. Annals of the New York Academy of Sciences. 1033(1). 168–176. 69 indexed citations
10.
Malamud, S.. (1995). At risk and abandoned: street children, AIDS and human rights.. PubMed. 6–7. 4 indexed citations
11.
Gold, Jay E., et al.. (1995). Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: Results in 36 patients. European Journal of Cancer. 31(5). 698–708. 12 indexed citations
12.
Berson, Anthony M., et al.. (1995). Chemoradiation in advanced nonsmall cell lung cancer. International Journal of Radiation Oncology*Biology*Physics. 33(1). 183–188. 9 indexed citations
13.
Vikram, Bhadrasain, et al.. (1994). Patterns of failure in carcinoma of the upper esophagus after alternating chemoradiotherapy. The American Journal of Surgery. 168(5). 423–424. 5 indexed citations
14.
Chadha, Manjeet, et al.. (1994). Squamous-cell carcinoma of the anus in HIV-positive patients. Diseases of the Colon & Rectum. 37(9). 861–865. 74 indexed citations
15.
Gold, Jay E., et al.. (1993). Adoptive chemoimmunotherapy using Ex vivo activated memory T‐cells and cyclophosphamide: Tumor lysis syndrome of a metastatic soft tissue sarcoma. American Journal of Hematology. 44(1). 42–47. 29 indexed citations
16.
Harvey, James C., et al.. (1993). Superior results with complete resection of Askin's tumor. Seminars in Surgical Oncology. 9(2). 156–159. 4 indexed citations
17.
18.
Vikram, Bhadrasain, et al.. (1993). Alternating chemo-radiotherapy for muscle-infiltrating bladder cancer. International Journal of Radiation Oncology*Biology*Physics. 27. 218–218. 1 indexed citations
19.
Vikram, Bhadrasain, S. Malamud, Jay E. Gold, et al.. (1991). Chemotherapy rapidly alternating with accelerated radiotherapy for advanced carcinomas of the hypopharynx and upper esophagus: A feasibility study. Head & Neck. 13(5). 415–419. 9 indexed citations
20.
Haubenstock, Alexander, et al.. (1985). Philadelphia-Chromosome-Negative Chronic Myelogenous Leukemia with Incomplete Trisomy 1q following Chemotherapy for Ovarian Carcinoma. Acta Haematologica. 74(3). 168–170. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Winston Ueno Breakdown of academic impact, for papers by J. Hartlapp Breakdown of academic impact, for papers by Pamela Bacon Breakdown of academic impact, for papers by Marcio M. Gomes Breakdown of academic impact, for papers by Yutaro Kato Breakdown of academic impact, for papers by Frederick M. Schnell Breakdown of academic impact, for papers by Ángel Segura Breakdown of academic impact, for papers by Yıldız Okuturlar Breakdown of academic impact, for papers by Elif Erkan Breakdown of academic impact, for papers by Yukiko Takahashi
Rankless by CCL
2026